Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
about
Targeting hypoxic response for cancer therapyDisseminated tumor cells and dormancy in prostate cancer metastasisProgress toward overcoming hypoxia-induced resistance to solid tumor therapyAXL kinase as a novel target for cancer therapyThe Receptor Tyrosine Kinase AXL in Cancer ProgressionCancer Cell Colonisation in the Bone MicroenvironmentHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsThe role of epithelial plasticity in prostate cancer dissemination and treatment resistanceAxl as a mediator of cellular growth and survivalGAS6 receptor status is associated with dormancy and bone metastatic tumor formationStrong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer.Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activityEndogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow.Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer.AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer.Molecular insights of Gas6/TAM in cancer development and therapy.New therapeutic targets for cancer bone metastasisImmunogenic, cellular, and angiogenic drivers of tumor dormancy--a melanoma view.Rat Prostate Tumor Cells Progress in the Bone Microenvironment to a Highly Aggressive Phenotype.Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?The Relationship Between Dormant Cancer Cells and Their Microenvironment.Biochemical Changes in the Niche Following Tumor Cell Invasion.Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival.Targeting Gas6/TAM in cancer cells and tumor microenvironment.AXL is a marker for epithelial-mesenchymal transition in esophageal squamous cell carcinoma.Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma.Mesenchymal Stromal Cells: Emerging Roles in Bone Metastasis.Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma secretory senescence
P2860
Q26767351-69A34B3E-0E58-41A8-8FB9-1A324C3D87B1Q26768484-11A4E6AF-EE9D-4B98-A44C-8293DFC69A3EQ26796405-E0729FBF-C485-4F8E-83DE-E89E6025890DQ26863442-174715C4-7590-48C8-B379-43DF67247E00Q28068756-EA95753E-F8A8-4DA5-AAF9-0D9D4AC124F5Q28072561-40EA5C10-400F-4532-96A5-0C40BD59D0CDQ28393898-8C82A0B2-CA10-4E18-91BA-FE78F8CE771AQ34505037-0A3F3444-02BC-40F1-9A5E-026A3D18364CQ34619118-9D2F109C-F98A-4E8E-AAB4-0B3DACB456D7Q34700694-346A5971-4638-468B-85A2-30C17854F678Q35892646-2997F9B7-14ED-478B-BDD4-BB3BD2CE4B25Q36903351-383103BA-3503-44FD-88E7-AE379FDEE8E5Q37295465-D7772F07-24A7-4D72-8183-0D6F0105E681Q37321961-19BD9D0A-765A-469D-89FC-A05F62AE9188Q37520184-0C3B46C9-AF44-4AF7-853C-98BE7047735BQ37684598-2E2A3F5B-655E-4223-9B7B-8D88AC60ABA7Q37745358-0CB011E8-0B14-476F-9230-E77BA29D3845Q38473066-5AFC92C9-EB00-4228-84F4-0D40A7F437CFQ38619615-76AAFC49-6602-4BF8-8576-C68FD680D810Q38785006-17A9B864-E237-4874-B9E8-095300FE39CBQ38936702-F0D3D3EC-DDE2-407C-8E0D-A583235D5A01Q38950549-1BE5BC67-562F-4A1C-B1FC-3DB753E7A2D6Q39041143-FEF61CE1-0019-4D59-9BB9-335741214EC7Q39157476-AF110C2F-0679-43D8-B1E2-F5EC26AC1318Q40112666-78A3C2B8-177A-4486-BB52-7BDA81258C71Q41612032-B997B55A-9DBF-44DC-AB15-EB2AACD5BF8FQ47701436-95F3B3E6-375F-4AB2-9EA8-26FFAE22499CQ50053695-EB010C85-7664-42A1-BF16-DCB4BE8A5617Q54340772-6B826223-90A6-42CF-BE23-68B5518C5EF2Q55235695-14416739-37F4-46C7-A914-50F9D78D7AB4Q58770630-0C45C0DC-43DE-47BB-9AF7-1C3BACD583C6
P2860
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
@ast
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
@en
type
label
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
@ast
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
@en
prefLabel
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
@ast
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
@en
P2093
P2860
P1476
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
@en
P2093
Aaron Havens
Anjali Mishra
Janice E Berry
Jeena Joseph
Jingcheng Wang
Jinkoo Kim
Samantha McGee
Younghun Jung
Yusuke Shiozawa
P2860
P304
P356
10.1158/1541-7786.MCR-11-0569
P577
2012-04-19T00:00:00Z